MINT-BETAHISTINE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

BETAHISTINE HYDROCHLORIDE

から入手可能:

MINT PHARMACEUTICALS INC

ATCコード:

N07CA01

INN（国際名）:

BETAHISTINE

投薬量:

16MG

医薬品形態:

TABLET

構図:

BETAHISTINE HYDROCHLORIDE 16MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

製品概要:

Active ingredient group (AIG) number: 0103555003; AHFS:

認証ステータス:

APPROVED

承認日:

2023-06-01

製品の特徴

PRODUCT MONOGRAPH
PR
MINT-BETAHISTINE
Betahistine Dihydrochloride Tablets
(8 mg, 16 mg and 24 mg)
Manufacture’s Standard
Anti-vertigo Agent
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Preparation:
May 17, 2023
Submission Control No: 257693
_MINT-BETAHISTINE Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
.....................................................................................................
5
DRUG INTERACTIONS
......................................................................................................
6
DOSAGE AND ADMINISTRATION
..................................................................................
7
OVERDOSAGE
....................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 8
STORAGE AND STABILITY
...........................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
12
PHARMACEUTICAL INFORMATION
...........................................................................
12
CLINICAL TRIALS
............................................................................................